Néovacs Raises 250,000 Euros through OCEANE-BSA Issuance
Néovacs announces a fundraising of 250,000 euros through the issuance of OCEANE-BSA subscribed by Hanover Square Investments. The net proceeds from this operation will be used to fund activities in the fields of asthma and allergies, as well as programs focused on mRNA strategies.
Allocation of Funds
The French biotech company allocates the net proceeds of 245,000 euros from this fundraising to finance its activities in the fields of asthma and allergies, as well as programs based on mRNA strategies. This operation is part of a financing agreement established with Hanover Square Investments, which had previously enabled a raise of 1,000,000 euros.
Details of the Issuance
The issued OCEANE-BSA has a nominal value of 250,000 euros. The initial subscriber, Hanover Square Investments, is tasked with ensuring a gradual fundraising for the company and is not intended to hold the securities permanently, but to sell them progressively on the market. This issuance does not require the establishment of a prospectus approved by the AMF.
